Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ginkgo Biloba Prevention Trial in Older Individuals

This study has been completed.
Office of Dietary Supplements (ODS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
National Center for Complementary and Integrative Health (NCCIH) Identifier:
First received: February 2, 2001
Last updated: March 11, 2013
Last verified: March 2013
Results First Received: March 27, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Conditions: Dementia
Alzheimer's Disease
Interventions: Drug: Ginkgo biloba
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment occured between September 2000 through June 2002 primarily using mass mailings from targeted lists such as voter's registration and commercially available lists. Some sites chose to supplement this approach with newspaper, radio and television ads plus newsletter articles, posters and community presentations.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
After mailing brochures to potential participants, we conducted a telephone screening followed by an in-person clinic visit to finalize eligibility. Randomization was done at a second visit within close proximity to the screening visit.

Reporting Groups
Ginkgo Biloba EGb 761 Ginkgo biloba 120 mg twice daily
Placebo Placebo twice daily

Participant Flow:   Overall Study
    Ginkgo Biloba     Placebo  
STARTED     1545 [1]   1524 [1]
COMPLETED     1448 [2]   1426 [2]
NOT COMPLETED     97     98  
Withdrawal by Subject                 97                 98  
[1] Randomized
[2] Reached endpoint of dementia, death or completion

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Ginkgo Biloba 120 mg twice daily, total 240 mg
Placebo Placebo 1 pill twice daily
Total Total of all reporting groups

Baseline Measures
    Ginkgo Biloba     Placebo     Total  
Number of Participants  
[units: participants]
  1545     1524     3069  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     0     0     0  
>=65 years     1545     1524     3069  
[units: years]
Mean (Standard Deviation)
  79.1  (3.3)     79.1  (3.3)     79.1  (3.3)  
[units: participants]
Female     702     716     1418  
Male     843     808     1651  
Region of Enrollment  
[units: participants]
United States     1545     1524     3069  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Incident Dementia   [ Time Frame: Brief neuropsychological testing every 6 months, detailed testing annually, average 6.1 years follow up ]

2.  Secondary:   Number of Participants With the Indicated Cardiovascular Disease or Mortality   [ Time Frame: 6 months ]

3.  Secondary:   Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.   [ Time Frame: 6 months/annually ]

  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Adverse event data were collected every six months at testing visits, and at interim 3 month adherence phone calls.
Additional Description No text entered.

Reporting Groups
Ginkgo Biloba EGb 761 Ginkgo biloba 120 mg twice daily
Placebo Placebo twice daily

Serious Adverse Events
    Ginkgo Biloba     Placebo  
Total, serious adverse events      
# participants affected / at risk     1000/1545 (64.72%)     961/1524 (63.06%)  
General disorders      
Death † 1    
# participants affected / at risk     197/1545 (12.75%)     188/1524 (12.34%)  
# events     197     188  
Bleeding † 1 [3]    
# participants affected / at risk     138/1545 (8.93%)     140/1524 (9.19%)  
# events     171     178  
All other SAEs † 1    
# participants affected / at risk     374/1545 (24.21%)     358/1524 (23.49%)  
# events     1627     1647  
Vascular disorders      
Coronary Heart Disease Total † 1 [4]    
# participants affected / at risk     211/1545 (13.66%)     204/1524 (13.39%)  
# events     285     259  
Stroke † 1 [5]    
# participants affected / at risk     80/1545 (5.18%)     71/1524 (4.66%)  
# events     88     82  
Events were collected by systematic assessment
1 Term from vocabulary, COSTART
[3] Gastrointestinal and all other
[4] Myocardial infarction, angina, angioplasty, coronary artery bypass graft, coronary heart disease death
[5] Ischemic, hemorrhagic and unknown

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information